Moreover, the small molecule inhibitor FB23-2, which targets FTO, suppressed tumor growth in a ccRCC mouse model, indicating that FTO is a potential druggable target and that FTO inhibitors hold therapeutic potential for tumor treatment [127]. The gene discussed is FTO; the disease is nonpapillary renal cell carcinoma.